Explore the latest in hepatitis C, including recent advances in diagnosis and antiviral treatment, prevention of complications, and more.
This review summarizes evidence regarding Black race and inequities in outcomes of hepatitis C virus (HCV) infection because of the high prevalence and absolute number of annual HCV-related deaths in Black populations relative to other racial and ethnic minority groups.
This cohort study investigates the correlates of risk for disinhibited behaviors using electronic health record data of individuals in the Million Veteran Program.
This nonrandomized controlled trial evaluates the feasibility, acceptability, and safety of providing hepatitis C virus treatment at diagnosis within a medically underserved population.
This cohort study evaluates whether alcohol use is associated with achieving a sustained virologic response when treating hepatitis C virus (HCV) infection with direct-acting antiviral therapy.
This cohort study examines variations in the receipt of direct-acting antiviral treatment in the 6 months following a new diagnosis for hepatitis C virus.
This cross-sectional study examines the prevalence of hepatitis C virus in pregnant women from 1998 to 2018, with a focus on changes since the start of the opioid epidemic in the late 1990s.
This cohort study examines the association of daily drainage volume and the incidence of complications, such as hyponatremia or acute kidney injury, in patients with cirrhosis and refractory ascites treated with devices.
This cross-sectional study identifies the shortcomings of current drug pricing indexes to estimate drug price inflation and considers a new approach.
This Medical News article is an interview with Francis S. Collins, MD, PhD, former National Institutes of Health director, and JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, about a historic Biden-Harris administration proposal to cure and prevent all hepatitis C infections in the US.
This Viewpoint introduces a proposed 5-year program from the Biden-Harris administration that would use direct-acting antivirals to eliminate hepatitis C in the United States.
This retrospective cohort study of 245 596 adults with CHC examines the association of hepatitis C virus elimination with the risk of liver and nonliver morbidity and overall mortality from 2010 to 2021.
This cohort study of patients within the Veterans Health Administration assesses the association between alcohol use disorder and receipt of direct-acting antiviral treatment for hepatitis C virus (HCV) infection.
This cohort study evaluates hepatitis C virus (HCV) treatment rates and patient characteristics associated with treatment in the era of direct-acting antivirals and during the COVID-19 pandemic.
This cohort study examines the risk of graft failure associated with donors with hepatitis C virus (HCV) infection before and after the introduction of direct-acting antiviral medications.
This cohort study examines the validity of the Kidney Donor Profile Index’s hepatitis C virus (HCV) penalty during the direct-acting antiviral era by comparing 5-year allograft survival between recipients of kidneys from HCV-RNA–positive donors vs HCV-RNA–negative donors.
Customize your JAMA Network experience by selecting one or more topics from the list below.